Flexible, Simplified, and Scalable Solutions for AAV Viral Vector Production
WEBINAR
The adeno-associated virus (AAV) is the leading viral vector for in vivo gene therapy. Currently, production is labor intensive and expensive because of adherent cell culture processes. The use of stirred-tank bioreactors allows scalable and robust processes to be developed to meet the most demanding needs for high-dose indications that target large organs, e.g. muscle, skin, or blood. High-performing cell culture media is also crucial to ensure consistent supply.
Here, we highlight the development of two suspension-based AAV upstream production platforms and describe simplified cell culture processes to enable an efficient and cost-effective solution for large-scale AAV production.
In this webinar, you will learn about:
- Market insights, overall process considerations & trends for AAV
- High-performing suspension-based AAV upstream production platforms: VirusExpress® and Sf-RVN®
- Simplifying and optimizing your HEK-based suspension cell culture processes with the new Cellvento® 4HEK
Speakers
David Loong, Ph.D.
Merck
Senior Consultant, Novel Modalities Asia Pacific, Bioprocessing Strategy
David Loong is our senior consultant, novel modalities APAC, bioprocessing strategy. Previously, David held roles as a senior scientist in biotech startups encompassing cell & gene therapy process development services, mAb discovery, and preclinical development. He has an extensive track record providing contract research services as a senior research scientist at AMRI Global, and as a product custodian for API GMP manufacturing at GSK. He holds a Ph.D. in synthetic organic chemistry from the Australian National University and a BTech(Hons) from Massey University (NZ) specializing in chemistry and process engineering.
Rain Lee
Merck
Regional Strategy Execution Manager, Upstream APeC
Rain Lee is a Regional Strategy Execution Manager for Upstream in Asia Pacific excluding China (APeC) at Merck. She partners with biopharma customers to translate process development challenges into scalable solutions, with a focus on upstream bioprocessing innovations—including cell lines, cell culture media, and intensified processes—as well as regional manufacturing strategies. Rain leads upstream go-to-market initiatives across APeC, helping customers accelerate development, reduce risk, and confidently transit from early development to GMP production.
Pharma and biopharma manufacturing
- Viral Vector Upstream Processing
Duration:1h
Language:English
Session 1:presented October 25, 2022